Compugen Ltd.

Ladies and gentlemen, thank you for joining us today. Welcome to CompuGen's third quarter 2021 results conference call. At this time, all participants are in the listen-only mode. An audio webcast of this call is available in the Investors section of CompuGen's website, www.cgen.com. As a reminder, today's call is being recorded. I would now like to introduce Yvonne Naughton, Head of Investor Relations and Corporate Communications. Yvonne, please go ahead.

Thank you, Operator, and thank you all for joining us on the call today. Today's call has been recorded and will be available on the Investor Relations section of our website. Joining me to present our prepared remarks are Anat Cohen-Diag, President and CEO, Henry Adewoy, Chief Medical Officer, and Ariat Krashen, Chief Financial and Operating Officer. For the Q&A session, we will also be joined by Eran Ofer, Vice President, Research and Drug Discovery. Moving to slide two. Before we begin, I would like to remind you that during this call, the company may make projections or forward-looking statements regarding future events, our business outlook, our development efforts and their outcome, our discovery platform, anticipated progress, results, and timelines for our program, financial and accounting-related matters, as well as statements regarding our cash position. We wish to continue that such statements reflect only the company's current beliefs, expectations, and assumptions. while actual results, performance, or achievements of the company may differ materially. These statements are subject to the known and unknown risks and uncertainties, and we refer you to the SEC filings for more details on these risks, including the company's most recent annual report on Form 20F, filed on February 25, 2021. The company undertakes no obligation to update projections or forward-looking statements in the future. With that, I now turn the call over to Anat.

Slide three, please. Thank you, Yvonne. Good morning and good afternoon, everyone, and welcome to our third quarter 2021 update. Today is an exciting day for Compugn with the announcement yesterday of the expansion of our strategic collaboration with BMS along with $20 million equity investment. And today, with the release of our free presentation at CITSEE, providing clinical, translational, and preclinical data that demonstrate strong execution across our differentiated clinical and scientific strategy, and the further support to our path forward. Indeed, to our knowledge, this is the first data presentation ever of a triple blockade of PVRIG, TGIT, and PD-1, and the first time data on antitumor activity of an FC-reduced effector function antitigic antibody is presented in a scientific conference. These dose escalation studies cleared our path to initiate multiple expansion cohort studies that are designed to broadly evaluate the inhibition of the genome axis in cancer immunotherapy and advance the therapeutic development of our two leading programs, COM701 and COM902. Henry will review the data from our dose escalation studies in the call, but before that, I'd like to share a high-level overview of the four key pillars of our long-term strategy and an overview of our clinical strategy. Moving to slide four, our first pillar is to advance the field of immuno-oncology research with the ultimate goal of developing new therapies. We have an impressive track record of driving the discovery of new targets and pathways in the immuno-oncology space with cutting-edge science published in peer-reviewed papers and development of a clinical stage pipeline derived from this science. Our clinically validated computational target discovery platform has generated a pipeline of exciting new candidates that are being evaluated in Phase I clinical trials by us and our partners, including our potentially first-in-class anti-PVRIG antibody, COM701, our high-affinity IgG4 FC-reduced effector function anti-TG antibody, COM902, Bapotilumab, an anti-ILDR2 antibody, which is being developed by Bayer, and AstraZeneca's TG bispecific antibody program, derived from COM902. I'm proud of our talented team of scientists with expertise in immuno-oncology and translational medicine and with our capabilities of driving the science of new unexplored biological pathways forward as we develop first-in-class therapeutics targeting these pathways. This takes us to our second pillar, which is to expand the number of patients responding to treatment by developing potentially first-in-class therapies for patients non-responsive or refractory to currently available therapies. Specifically, the unique biology we unlocked for the PVRIG pathway following its discovery serves as the basis for our assessment of the different combinations of PVRIG TGIT, and PD-1 inhibitors in select biomarker-informed tumor types, generally not responsive to checkpoint inhibitors. What makes us differentiated beyond the discovery of this pathway and uncovering its potential role within the genome axis is that we are the only company evaluating combinations of PVRIG, TGIT, and PD-1 blockers in the clinics. It is exciting to be the leaders in the genome axis, especially considering the recent advancements and raising interest by followers in this area. Maximizing the value for patients is our third pillar and speaks to our goal of bringing new treatments to market as rapidly and efficiently as possible. To support us on our journey, we seek collaborations and strategic partnerships with leading biopharma companies with complementary capabilities worldwide to expedite our early and clinical stage programs and bring them to the market. In addition to our partnership with BMS, our partnerships with AstraZeneca and Bayer also highlight the value of our strategy to broaden the opportunities of our products to reach more patients. And finally, our fourth pillar is to protect our innovations while developing drugs for patients through securing IP rights. We have developed a strong IP portfolio with potentially broad protection for drug candidates. Now moving to slide five. We have employed a comprehensive clinical strategy to assess our Dynamaxis hypothesis. we designed multiple combination studies evaluating the simultaneous blockade of the three pathways and subsets. All are running now in parallel in multiple tumor types selected in a biomarker-informed manner. Each of these studies include comprehensive translational data analytics in order to further support our drug's mechanism of action and discover and evaluate potential biomarkers that may be of relevance for future patient selection. In addition, our multiple combination studies are being pursued in some overlapping indications. This is by itself will allow us to evaluate the contribution of each drug in this combination. And focusing mainly on non-responsive tumors, should help to differentiate the contribution of COM701. The data from these multiple studies will allow us to select the combinations and tumor types to progress our program. Moving now to slide six. I'd like to say that we delivered on all our targeted milestones for this quarter and for the year. 2021 played a major role in further solidifying our leadership position in the genome axis with steady and impressive execution. We've completed all our dose escalation studies, including our COM701 monotherapy, COM701 plus nivolumab, COM902 monotherapy, and triple combination studies. We've now progressed to expansion cohorts across all our programs, which allows us to focus on select indications through our translational data-driven approach. Our accomplishments through 2021 also reinforce the power of our partnering strategy in diversifying our portfolio, with a milestone payment from AstraZeneca after the first patient dose in their phase one study of a TG-Bi-specific derived from our COM902. In addition, we were thrilled to announce the expansion of our collaboration with BMS and believe the recent $20 million strategic equity investment in Compugen strengthens our relationship and the goal of both companies to bring innovative therapies to cancer patients through the advancement of our clinical studies conducted under our collaboration. As part of the expansion of the collaboration, a Joint Steering Committee has been formed to facilitate strategic oversight and guidance for the programs run under the collaboration. This committee will run alongside the existing Joint Development Committee, which acts at an operational level. With that, I'd like to turn the call over to Henry for him to provide an overview of our data released at CITSE today. Henry?